Skip to content
Screener

Reported August 13, 2026 · Before market open

Revenue$100.0KMiss by $16.6M
EPS-$2.32Miss by $2.16
Revenue estimate$16.7M
EPS estimate-$0.17

Next report

Feb 11, 2027 (in 3 months)
Revenue estimate$1.1M
EPS estimate-$0.42

Financials

Q2 2026

Income statement

See full
Revenue$148.0K—
Operating income-$50.9M-39.3%
Net income-$52.5M-50.7%
EPS (diluted)-$2.32+89.6%

Balance sheet

See full
Cash & equivalents$1.1B+1,252%
Total debt$46.8M—
Total equity$1.0B+330%
Total assets$1.2B—

Valuation & ratios

Valuation

as of 06/30/26
See full
Market cap$3.35B—
Enterprise value$2.31B—

Returns & leverage

See full
Debt / equity0×—
Current ratio17.9×—

Versus estimates

Revenue

Q3 2026$2.1MBeat by $1.7M
Q2 2026$100.0KMiss by $16.6M

Diluted EPS

Q3 2026-$0.36In line
Q2 2026-$2.32Miss by $2.16

FAQ

When did Parabilis Medicines report Q2 2026 earnings?
Parabilis Medicines (PBLS) reported Q2 2026 earnings on August 13, 2026 before market open.
What were Parabilis Medicines's Q2 2026 revenue and EPS?
Parabilis Medicines reported revenue of $100.0K and eps of $-2.32 for Q2 2026.
Did Parabilis Medicines beat estimates in Q2 2026?
Revenue missed the consensus estimate of $16.7M by $16.6M. EPS missed the consensus estimate of $-0.17 by $2.15.
Where can I find Parabilis Medicines's Q2 2026 SEC filings?
You can read the 8-K earnings release (0001193125-26-347869) and the 10-Q periodic report (0001193125-26-349168) directly on SEC EDGAR. The filing index links above go to sec.gov.